Ads
related to: atopic dermatitis- FAQs
Find Answers To Your Questions
& Understand Treatment Now
- Treatment Support
Discover Educational Resources
& Get Financial Support Information
- Home
Official Patient Website—
Get Treatment Info Today.
- Getting Started
Learn More About Dosing Schedules
Find Answers To Your Questions
- Support Resources
Sign Up And Learn More About The
Patient Education Program Today.
- Sign Up
Register Or Activate Your Card—
Find Out If You're Eligible Today.
- FAQs
Search results
What’s Your Story? Contest Finalists
The Scientist· 6 days agoEarlier this year, The Scientist, in partnership with Thermo Fisher Scientific, launched What’s Your Story?, a science writing competition that...
Morning Brew: MicroStrategy Soars on MSCI Inclusion, Walmart Bea
Guru Focus· 6 days agoToday's stock market is showing positive signs with slight gains across major indices. Here's a...
J&J hooks Proteologix for $850M cash, reeling in a roster of early bispecifics
FierceBiotech· 6 days agoJohnson & Johnson is shelling out $850 million to buy Proteologix, getting hold of a young roster of...
Nektar Therapeutics (NASDAQ:NKTR) Given Consensus Recommendation of “Hold” by Analysts
ETF DAILY NEWS· 3 days agoNektar Therapeutics (NASDAQ:NKTR – Get Free Report) has received an average recommendation of “Hold” from the five ratings firms that are covering the stock, Marketbeat reports. Jefferies Financial ...
Vanguard Personalized Indexing Management LLC Raises Position in Incyte Co. (NASDAQ:INCY)
ETF DAILY NEWS· 3 days agoVanguard Personalized Indexing Management LLC boosted its stake in Incyte Co. (NASDAQ:INCY – Free Report) by 30.4% during the fourth quarter, according to its most recent 13F filing with the ...
Zacks Research Weighs in on AbbVie Inc.’s FY2024 Earnings (NYSE:ABBV)
ETF DAILY NEWS· 5 days agoAbbVie Inc. (NYSE:ABBV – Free Report) – Research analysts at Zacks Research raised their FY2024 EPS estimates for AbbVie in a note issued to investors on Tuesday, May 14th. Zacks Research analyst ...
Celldex Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Prurigo Nodularis -...
Benzinga· 7 days agoCelldex Therapeutics, Inc. CLDX today announced that the first patient has been dosed in the Company's Phase 2 subcutaneous study of barzolvolimab in prurigo nodularis (PN). Barzolvolimab is ...
J&J (JNJ) to Boost Dermatology Portfolio With New Acquisition
Zacks· 5 days agoJohnson & Johnson (JNJ) inks deal to acquire Proteologix, Inc. for $850 million in cash. The transaction is expected to be closed in mid-2024.
Mizuho Boosts Arcutis Biotherapeutics (NASDAQ:ARQT) Price Target to $18.00
ETF DAILY NEWS· 4 days agoArcutis Biotherapeutics (NASDAQ:ARQT – Free Report) had its price target lifted by Mizuho from $17.00 to $18.00 in a report issued on Wednesday, Benzinga reports. They currently have a buy rating ...
Needham & Company LLC Increases Arcutis Biotherapeutics (NASDAQ:ARQT) Price Target to $18.00
ETF DAILY NEWS· 5 days agoArcutis Biotherapeutics (NASDAQ:ARQT – Get Free Report) had its target price lifted by equities researchers at Needham & Company LLC from $16.00 to $18.00 in a note issued to investors on Wednesday ...
Ads
related to: atopic dermatitis